Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review

Sudeep Gupta1*, Shona Nag2, Shyam Aggarwal3, Amit Rauthan4 and Narayanankuty Warrier5

Abstract
Epithelial ovarian cancer (EOC) is usually diagnosed late at an advanced stage. Though EOC initially responds to treatment, the recurrence rate is pretty high. The efficacy of different targeted therapies reduces with each recurrence. Hence there is need of effective maintenance therapy in recurrent EOC. Recently, polyADP-ribose polymerase (PARP) inhibitors (PARPi) have been approved both for initial treatment of EOC and as its maintenance treatment. PARPi have also been found to act regardless of BRCA status or homologous recombination (HR) deficiency. Several trials testing PARPi early in maintenance therapy are in progress and their results will shed light on the optimal timing of maintenance therapy that gives the most benefit with least toxicity. Right patient selection for maintenance treatment is also a challenge. Hence, though PARPi are emerging as a promising maintenance treatment in recurrent EOC with prolongation of progression free survival (PFS), results from further trials and overall survival (OS) data from current trials are awaited to fulfill the gaps in understanding the role of this pathway in treatment of EOC. This review discusses the current therapies for EOC, challenges in the treatment of recurrent EOC, recent developments and trials in recurrent EOC maintenance with special focus on PARPi and future perspectives.

Keywords: PARP inhibitors, Maintenance recurrent ovarian cancer, Epithelial ovarian cancer, Olaparib, Niraparib, Rucaparib

Introduction
Globally, ovarian cancer (OC) is the seventh most common malignancy diagnosed among women and eighth leading cause of cancer mortality [1]. In 2018, United States is burdened with approximately 22,240 new cases and 14,070 deaths related to OC [2]. Among Indian women, ovarian cancer is the third leading cause of cancer after breast and cervical cancer. The age-adjusted incidence rates of OC vary between 5.4 and 8.0 per 100,000 persons in different parts of the country [3].

About 85–90% of all ovarian cancers are epithelial in origin, and around 70% of all epithelial ovarian cancers (EOCs) are high-grade serous (HGS) adenocarcinoma [4]. The term EOC often includes fallopian tube carcinoma and primary peritoneal carcinoma, as they have the same treatment and prognosis even though they are distinct from each other [4, 5].

Treatment after first-line therapy in EOC is contingent to platinum-free interval (PFI) and the side-effects from the previous therapy. Platinum-based chemotherapy (PBC) remains the mainstay of treatment in platinum sensitive disease (progression after 6 months of previous therapy). Many treatment options are being tried in recurrent EOC setting including targeted therapy with vascular endothelial growth factor (VEGF) inhibitors such as bevacizumab and tyrosine kinase inhibitors (TKI) such as pazopanib and nintedanib. While bevacizumab has shown benefit in recurrent setting, data on the efficacy of pazopanib and nintedanib in recurrent setting in platinum sensitive or platinum resistant disease (depending on whether progression occurred more than 6 months or less than 6 months after completing initial PBC is very limited) [6, 7].

Others, such as topotecan, pegylated liposomal doxorubicin (PLD), docetaxel, and etoposide have been investigated in platinum resistant disease.
However, if there is no clinical benefit after two lines of therapy, there is minimal likelihood of benefit from additional lines of therapy [6].

EOC is a challenge to treat because of its notoriety at recurrence with reduced benefit (<20%), increasing toxicities, and poor quality of life with each subsequent line of therapy. Even with the newer therapies for recurrence, there has been no increase in progression free survival (PFS) after first-line therapy although overall survival (OS) is now longer [8]. Hence, there is an unmet need to optimize treatment in recurrent EOC. With increasing consensus that goals of therapy in recurrent EOC should be palliation of cancer-related symptoms, maintenance of quality of life, and extension of life, there is a lot of interest and research focusing on maintenance treatments for recurrent EOC [9]. In this concept, EOC is treated with maintenance dose therapy while the response to previous line PBC is still lingering. The concept is based on the hypothesis that advanced stage EOC usually has different clonal subpopulation of malignant cells of which some eventually become resistant to first-line chemotherapy, while others may respond to continuous maintenance dose therapy [10].

Poly ADP-ribose polymerase (PARP) inhibitors (PARPi) (olaparib, rucaparib, and niraparib) have emerged as one of the best approved target therapy options for recurrent EOC, especially in case of platinum-sensitive recurrent ovarian cancer (PSROC) [11–16]. This review will therefore focus on maintenance treatment of EOC with special emphasis on platinum sensitive disease and PARPi.

**Challenges in treating EOC**

There is tremendous amount of research and focus on EOC as it presents in advanced stages and is the most fatal of the gynecologic malignancies. Since EOC does not have symptoms specific to cancer, there are no early screening and detection modalities [17, 18]. Thus, around 75% of women are diagnosed in advanced stage disease (FIGO IIIc or IV) [17, 18].

**Utility of laboratory markers in the diagnosis of EOC recurrence**

Also, there are no effective lab tests known to monitor response to therapy in EOC. Though serum tumor marker CA125 is being used for initial diagnosis and for monitoring of response to chemotherapy, there is no evidence that a raised CA125 concentration alone can predict a survival benefit. Some patients with EOC present with rising CA125 levels despite having no signs and symptoms of recurrence. Treatment is a major challenge in these patients [19, 20]. Hence, there is need for other tumor biomarkers to assess the response to therapy.

**Recurrent EOC and common genetic mutations**

Hereditary mutations in the BRCA1 or BRCA2 (BRCA1/2) genes occur more frequently in patients with platinum-sensitive EOC than platinum-resistant EOC [12], and these patients respond better to therapy and have greater survival benefits than women without the mutation [21]. However, routine BRCA testing and BRCA based treatment decisions are still at a nascent stage in India [22].

Newly diagnosed EOC is conventionally treated with de-bulking surgery and PBC in either neoadjuvant or adjuvant setting. However, even after being in full remission on first-line therapy, about 70–85% of patients with EOC relapse and median survival for patients with recurrent disease ranges from 12 months to 24 months [23]. Even with good response to treatment and survival after first recurrence on PBC, this treatment is rarely curative [23].

**Importance of platinum free interval in platinum sensitive relapsed ovarian Cancer**

Upon recurrence in EOC, the choice of second-line chemotherapy is guided by the duration of response (DoR) to the prior PBC, also known as platinum-free interval (PFI), which is the time between completing initial PBC and progression. In patients with recurrent EOC, PFI is the most important predictor of response to subsequent lines of chemotherapy and the most important prognostic factor for PFS and OS. The longer the PFI, the higher the response rate (RR) and longer the duration of response [23].

**PFI and treatment responses in platinum sensitive relapsed EOC**

Though patients with a PFI more than 6 months have been considered as platinum-sensitive, those with a PFI more than 12 months are considered definite or highly platinum sensitive, and those falling in the group with PFI of 6 to 12 months are now considered partially platinum-sensitive (PPS). However, treatment with platinum containing doublets in the PPS group gives unsatisfactory results with RR of only 25–30% to the subsequent PBC. The most effective regimen to be used in PPS is still uncertain and requires further research [7, 23–25].

It has been seen that with each recurrence the sensitivity and response to PBC decreases dramatically. Second-line PBC has a response of approximately 50–65% [25]. In a study, 51.6% of the patients showed clinical response to second-line therapy but the response dramatically reduced to only 11.9% in third-line chemotherapy [26]. Response profiles of late lines of non-platinum-containing regimens are in the range 10–15% with a PFS benefit of about 3 to 4 months, and OS benefit of around 12 months [27]. In three large European studies comprising of 1620 patients with OC, median PFS after the first, second, third, fourth, and fifth relapse was 10.2 [95% confidence interval (CI)
9.6–10.7], 6.4 (5.9–7.0), 5.6 (4.8–6.2), 4.4 (3.7–4.9), and 4.1 (3.0–5.1) months, respectively. Median OS after the first, second, third, fourth, and fifth relapse was 17.6 (95% CI 16.4–18.6), 11.3 (10.4–12.9), 8.9 (7.8–9.9), 6.2 (5.1–7.7), and 5.0 (3.8–10.4) months, respectively [28].

Current status of selecting patients based on platinum sensitivity
Until recent years, recurrent EOC had no treatment option other than repeated courses of chemotherapy in second-line setting and beyond, with most patients eventually becoming resistant to PBC. Thus, selecting patients based on platinum sensitivity lost meaning after second-line therapy [25, 29, 30]. Hence, there is an unmet need for newer therapies in this area like PARPi and the concept of maintenance is gaining significance.

Treatment options for platinum sensitive versus platinum resistant recurrent EOC
Guided by PFI, either chemotherapy or targeted therapies are used for EOC recurrence.

Chemotherapy
Platinum sensitive patients are carefully selected for various combinations of PBC comprising of carboplatin or cisplatin in combination with paclitaxel, gemcitabine, PLD, or (with or without) bevacizumab [6, 7]. Combination therapy has been demonstrated to have better PFS and OS advantages over single platinum-agents [7, 23, 25].

If progression after first-line therapy occurs in less than 6 months after cessation of chemotherapy, the disease is considered platinum-resistant. During treatment EOCs can become platinum refractory, which means progression occurs during chemotherapy or within 1 month of cessation of chemotherapy [25, 29, 30]. The prognosis is poor for platinum-refractory and platinum-resistant patients. A non-platinum regimen is generally considered the most appropriate approach in these patients [23, 24]. In platinum-resistant patients, single agent non-platinum-containing therapies like PLD, paclitaxel, gemcitabine, or topotecan are recommended. Bevacizumab could be added in carefully selected patients [6].

In patients with partially sensitive recurrent EOC, the MITO-8 trial supports the use of PBC as platinum sensitive drugs prolong PFI and improve quality of life compared to non-platinum-based therapy [30, 31]. However, when platinum is not an option due to anaphylaxis to platinum compounds, trabectedin (MITO15 phase II trial [NCT01772979]) or PLD with trabectedin (phase 3 OVA-301 study) can be considered. In these patients with anaphylaxis to platinum compound, platinum sensitive patients derived more benefit than platinum resistant patients and patients with BRCA mutation had longer PFS and OS [7, 32, 33].

Targeted therapies
Approved therapies
Molecularly targeted inhibitors such as VEGF inhibitors (i.e., bevacizumab) and PARPi (i.e., olaparib, rucaparib, and niraparib) have emerged as treatment options in patients with advanced EOC after multiple prior lines of chemotherapy. Careful patient selection is required for bevacizumab and PARPi therapy, however, the criteria for patient selection are still evolving [25].

Bevacizumab, in combination with paclitaxel, PLD, or topotecan is approved for the treatment of patients with platinum-resistant recurrent EOC after maximum 2 prior lines of chemotherapy [27, 34]. Bevacizumab benefit has been demonstrated in platinum resistant setting in the AURELIA study [27]. In the platinum sensitive setting, bevacizumab has been tested in the OCEANS study and GOG-213 study [35–37]. Bevacizumab along with PBC like carboplatin-gemcitabine or carboplatin-paclitaxel is tested in MITO16 and MANGO-2 trials and in the phase III BOOST trial (NCT01462890) [31, 38, 39]. Bevacizumab monotherapy has also shown some clinical activity in platinum resistant patients with a clinical response rate of 16–21% in 1 to 3 prior lines of chemotherapy, and 13–16% in later lines of therapy [25].

PARPi have been the most studied, most effective, and least toxic in platinum sensitive recurrent EOC both as treatment and as maintenance [11]. These have been discussed in detail in a separate section.

Therapies under clinical development
TKIs like pazopanib (a multikinase inhibitor of VEGFR1–3, c-Kit and platelet-derived growth factor receptor α and β), trebananib (a fusion protein that selectively binds angiopoietin 1 and 2, preventing signaling through Tie-2 receptor), cediranib (a potent oral inhibitor of all 3VEGF receptor tyrosine kinases), nintedanib (a multi-kinase inhibitor); and immune checkpoint inhibitors like atezolizumab are being tested in various settings [7]. Success of targeted therapies lies on their specific inhibition of a driving molecule or pathway resulting in a tumor response rate of around 50–70% and a disease control rate of at least 80% [40].

Pazopanib, had demonstrated the PFS advantage in platinum-resistant and refractory OC (phase II trial: MITO-11; NCT01644825) [7, 30].

The immune checkpoint inhibitor atezolizumab in combination with PBC and bevacizumab is being tested in platinum sensitive setting in phase III randomized, double-blinded ATALANTE (NCT02891824) trial, and in AGO-OVAR 2.29 trial which is in a platinum resistant setting. Other combination trials include phase II study (EORTC-1508/NCT02659384) investigating atezolizumab with bevacizumab or acetylsalicylic acid and
Maintenance therapy in recurrent EOC

A comprehensive analysis of 13 randomized placebo-controlled trials studying targeted maintenance therapy in OC showed that both PFS and OS improved compared to placebo (PFS: HR = 0.84, 95% CI 0.75 to 0.95, \( p = 0.001 \); OS: HR = 0.91, 95% CI 0.84 to 0.98, \( p = 0.02 \)). However, treatment with targeted maintenance therapy was associated with increased incidence of adverse events (AEs) such as nausea, vomiting, diarrhea, fatigue, and hypertension which required dose reductions [41].

Though several maintenance therapies for recurrent OC have been tested, but only PARPi (niraparib, rucaparib, olaparib) have been approved by the FDA and/or European Medical Association (EMA) [7]. Paclitaxel has been tested in GOG 212 trial which failed to show OS benefit and demonstrated increased toxicities after complete response to first-line therapy [42]. Bevacizumab has been investigated in GOG 218, and NCT02022917 study with inconclusive evidence of benefit in maintenance and in ICON7 with no evidence of benefit in PFS or OS in first line maintenance except in a subset of high risk patients [43, 44]. Very few patients in high risk sub-set in ICON7 received bevacizumab in recurrent setting, and hence its use in maintenance in recurrent EOC is not known [45].

The review by Cortez et al. has shown that PARPi inhibitors such as niraparib in NOVA trial, olaparib in SOLO-2; and rucaparib in ARIEL-3 trials have demonstrated positive results in their respective clinical trials [7].

Pazopanib monotherapy was evaluated inAGO-OVAR16 (NCT00866697) trial and though it showed improved median PFS versus placebo 17.9 vs 12.3 months, respectively in platinum-sensitive maintenance (hazard ratio [HR], 0.77; 95% CI 0.64 to 0.91; \( p = 0.0021 \)), further studies are required to validate these findings as OS benefit has yet not been demonstrated [30, 46].

Nintedanib has been successfully studied in a phase 3 trial in combination with chemotherapy followed by maintenance monotherapy (AGO-OVAR 12/NCT01015118). Nintedanib demonstrated significant improvement in median PFS in the treatment group compared with control group (17.2 versus 16.6 months; HR = 0.84; 95% CI 0.72–0.98; \( p = 0.024 \)) [47]. In their review, Elit & Hirte reported results of a phase 2 trial of nintedanib (NCT00710762) as maintenance in patients with resistant or partial PSROC which showed a higher PFS rate of 16.3% at 36 weeks compared with 5% in placebo group (HR = 0.68; 95% CI 0.44–1.07; \( p = 0.07 \)) [48]. Evaluation of nintedanib in bevacizumab resistant, persistent, or recurrent EOC which does not progress for at least 6 months is in progress (NCT01669798) [7].

Preliminary data of pembrolizumab in combination with first-line PBC, followed by pembrolizumab maintenance showed promise in a small clinical trial of advanced OC presented at the 2018 Society of Gynecologic Oncology Annual Meeting [49]. Immune checkpoint inhibitors like atezolizumab are being tested in combination with bevacizumab and PBC in the ATALANTE (NCT02891824) trial [7].

Thus, both chemotherapy and non-PARPi targeted therapies (Table 1) either failed to give a conclusive benefit in EOC maintenance or the trials are still in progress with results awaited.

Application of PARPi inhibitors in the treatment of recurrent ovarian Cancer

PARP (Fig. 1) includes a class of 17 enzymes that interrupt DNA repair, disrupt stability, and cause cell death by their action on single-strand DNA breaks or base excision repair (BER) [7].

PARPi could be useful in HGS ovarian cancers (HGSOC) as they have detectable germline and somatic mutations. Another notable characteristic seen in many HGSOC is DNA methylation of genes (e.g. BRCA1/2) which participate in homologous recombination (HR) DNA repair during epigenetic silencing. Approximately 30% of HGSOCs have BRCA1/2 mutation and silencing which frequently cause diminished HR activity. HR DNA repair is a critical step in accurate repair of DNA (Fig. 2) following double strand break (DSB) [16, 40]. In addition, PARPi are selectively lethal in HR deficient (including BRCA1/2-mutated) cancers as they inhibit alternate DNA repair pathways such as BER and single-strand break repair [16, 40].

However, in patients with PSROC, olaparib has been shown to significantly improve PFS regardless of BRCA mutation and niraparib showed improved PFS regardless of BRCA mutation and homologous recombination deficiency (HRD) status [7, 16]. This indicates that apart from HR genes, there could be other potential predicative biomarkers and mechanisms for PARPi sensitivity. It also suggests that although efficacy of both olaparib and niraparib is highest in BRCA1-mutated population, other patients may benefit too as improved PFS advantage was seen in wild-type BRCA positive patients with low genetic loss of heterozygosity (LOH) [7, 16].

The only accepted predictors of a response to PARPi are cisplatin sensitivity and presence of BRCA1 or BRCA2 mutations [7].. However, the optimal timing and duration of administration of PARPi is still a matter of debate. Based on data obtained from olaparib trials, it appears that the efficacy of PARP inhibition decreases with increasing lines of chemotherapy. This suggests that use of PARPi earlier in OC treatment may be more beneficial [50].
Though PARPi have side-effects including anemia, increase in creatinine, myelodysplastic syndrome (MDS) and acute leukemia (Table 2), they are usually not as severe as those observed with chemotherapy or with other targeted therapies and are easily managed with dose reductions and modifications. About, ≤1% patients in both olaparib and rucaparib studies have also developed MDS/acute myeloid leukemia, highlighting the need to monitor patients for hematologic toxicities [13, 14].

In the treatment of advanced recurrent OC, PARPi continues to be tested in three distinct settings, especially after 2–3 or more prior lines of PBC [7, 11, 16]:

1) Monotherapy (olaparib in relapsed germline BRCA + ve EOC in SOLO3/NCT02282020; rucaparib versus chemotherapy in BRCA + ve EOC in ARIEL4/NCT02855944)

2) Maintenance therapy (discussed in a separate section): (ENGOT-OV16 NOVA/NCT01847274, SOLO 2/NCT01874353, ARIEL3/NCT01968213)

3) Combination therapy (niraparib versus niraparib-bevacizumab ENGOTOV24/AVANOVA/ NCT02354131; olaparib or cediranib maleate and olaparib in NCI-OVM1403/NCT02446600; olaparib with paclitaxel and carboplatin versus carboplatin and paclitaxel alone in patients with PSROC in NCT01081951

### Table 1 Overview of investigational non-PARP inhibitors in EOC maintenance

| Trial name | Drug | Mono/Combo; Phase | Patient population and key eligibility | N | Treatment arms | Primary endpoint | Results |
|------------|------|-------------------|----------------------------------------|----|----------------|-----------------|---------|
| GOG 212 [42] | Paclitaxel | Mono; Phase III | Advanced EOC in complete response | 1157 | Pac IV or CT-2103 (PP) | OS | No improvement in OS; increased toxicities |
| ICON 7 [44] | Bevacizumab | Combo; Phase III | Newly diagnosed early or advance EOC, first line | 1528 | C + Pac vs C + Pac + bev | PFS and OS | No improvement in PFS. No improvement in OS; restricted mean survival time chemo vs bev group 44.6 months (95% CI 43.2–45.9) vs 45.5 months (CI 44.2–46.7); log-rank (p = 0.85); Benefit only in high-risk subset: mean OS 34.5 months (95% CI 32.0–37.0) vs 39.3 months (37.0–41.7) (log-rank p = 0.03). |
| GOG 218 [43] | Bevacizumab | Combo; Phase III | Newly diagnosed advance EOC | 1873 | C + Pac (TC group) vs C + Pac + bev (TCP group) vs C + Pac + bev followed by bev maintenance | PFS and OS | PFS improvement of 3.8 months (10.3 for standard chemotherapy, 14.1 months for the maintenance regimen), Median OS was not significantly different between arms |
| NCT02022917 [43] | Bevacizumab | Combo; Phase II | Extensive stage IIIC or IV EOC | 27 | Postoperative PBC + adjuvant maintenance bev | AE | Ongoing; study completion |
| ATALANTE (NCT02891824) | Atezolizumab | Combo; Phase III | Late relapse EOC | 405 | Atezolizumab in combination with PBC + bev administered concurrent to chemotherapy and in maintenance | PFS | Ongoing; study completion 2023 |
| AGO-OVAR16 (NCT00866697) [30, 46] | Pazopanib | Mono; Phase III | Platinum-sensitive maintenance in EOC | 940 | Pazopanib 800 mg OD maintenance in EOC patients who did not progress after one line of chemotherapy | PFS | Improved median PFS vs placebo 17.9 vs 12.3 months, respectively (HR: 0.77; 95% CI, 0.64–0.91; p = 0.0021) |

PP paclitaxel poliglumex, C carboplatin, Pac paclitaxel, PLD pegylated liposomal doxorubicin, PBC platinum-based chemotherapy, N patient accrual, PFS progression free survival, OS overall survival, HR hazard ratio, CI confidence interval, TC Chemotherapy, TCP paclitaxel + carboplatin + bevacizumab, Bev bevacizumab, AE adverse events, EOC epithelial ovarian cancer, OD Once a day

**PARP Inhibitor Monotherapy in recurrent EOC (Table 3)**

**Approved therapies**

In late 2014, olaparib received accelerated FDA approval as monotherapy for patients with advanced OC previously treated with ≥3 lines of chemotherapy and harboring deleterious or suspected deleterious germline BRCA (gBRCA) mutations. Olaparib was granted accelerated approval based on an objective response rate (ORR) of 34% (46/137; 95% CI 26–42) and median duration of response (DOR) of 7.9 (95% CI 5.6–9.6) months in a heavily pretreated (≥3 lines of therapy) 137 patients with advanced OC who had a germline BRCA mutation in Study 42 [56]. This accelerated approval was contingent...
upon verification of clinical benefit from two trials: SOLO 2 which studies olaparib in PSROC with a BRCA1/2 mutation who had received at least two lines of previous chemotherapy [51] and the phase 2 LIGHT study (NCT02983799) which assesses the efficacy and safety of olaparib in patient cohorts stratified by use of different HRD genetic tests [57].

SOLO 3 is an ongoing phase III randomized trial of olaparib vs. physicians’ choice of four chemotherapy options in patients with platinum-sensitive germline BRCA mutant HGSOC, who had two or more lines of PBC [7, 11]. The results of the SOLO3 were recently presented at ASCO 2019 by Penson and colleagues showed a statistically significant and clinically meaningful

| Table 2 Side effects of PARP inhibitors |
|----------------------------------------|
| **Grade 3 and 4 Adverse Events**        |
| Hematological                          |
| Anemia 38 (18%)                         |
| Neutropenia 8 (4%)                      |
| Thrombocytopenia 2 (1%)                 |
| Neutropenia 72 (19.6%)                  |
| Thrombocytopenia 124 (33.8%)            |
| Hypertension 30 (8.2%)                  |
| Fatigue 5 (3%)                          |
| Nausea 5 (3%)                           |
| Vomiting 5 (3%)                         |
| Leukopenia 1 (2%)                       |
| Neutropenia 1 (2%)                      |
| Thrombocytopenia 1 (2%)                 |
| Total 35 (18%)                          |

| Non-hematological                      |
| Fatigue 8 (4%)                         |
| Abdominal pain 5 (3%)                  |
| Nausea 5 (3%)                          |
| Vomiting 5 (3%)                        |
| Hypertension 30 (8.2%)                 |
| Fatigue 5 (3%)                         |
| Nausea 5 (3%)                          |
| Leukopenia 1 (2%)                      |
| Nausea 2 (4%)                          |
| Metabolism/nutrition                   |
| Total 10 (3.0%)                        |

| Serious Adverse Events                  |
| Total 110 (30%)                        |
| Individual Anemia 7 (4%)               |
| Abdominal pain 3 (2%)                  |
| Intestinal obstruction 3 (2%)          |
| ARIEL2: total 50 (25%)                 |
| ARIEL3: total 78 (21%)                 |
| ARIEL2: Intestinal obstruction 10 (5%) |
| Anemia 9 (4%)                          |
| ARIEL3: Anemia 16 (4%)                 |
| Pyrexia 6 (2%)                         |
| Vomiting 6 (2%)                        |
| Intestinal obstruction 3 (1%)          |
| Total 12 (24%)                         |

| Dose Changes due to Adverse Events     |
| Dose reductions 49 (25%)                |
| Discontinuations 21 (11%)               |
| ARIEL2: Dose reductions: 80 (39%)       |
| Discontinuations: 19 (9%)               |
| ARIEL3: Dose reductions: 203 (55%)      |
| Discontinuations: 50 (13%)              |
| Dose Reductions: 31 (62%)               |
| Discontinuations: 31 (62%)              |
ORR and PFS benefit with olaparib versus non-platinum based chemotherapy.

In late 2016, rucaparib, another PARP inhibitor was approved as monotherapy for patients with PSROC that progressed with ≥2 lines of chemotherapy and harboring deleterious BRCA mutation (germline or somatic). The accelerated approval was based upon positive results from ARIEL2 Part 1 study, which demonstrated significantly longer PFS in the BRCA mutant (hazard ratio [HR] 0.27, 95% CI 0.16–0.44, \( p < 0.0001 \)) and LOH high (0.62, 0.42–0.90, \( p = 0.011 \)) subgroups compared with the LOH low subgroup. Part 2 of the ARIEL2 trial is ongoing (NCT01891344) [14, 53, 54]. Ongoing studies (Study 10 Part 2B, ARIEL2 Part 2, ARIEL4) are evaluating rucaparib treatment in both platinum sensitive and resistant patient population [59].

**PARP inhibitors combination therapy in recurrent EOC (Table 3)**

Various olaparib or veliparib combinations with chemotherapy have been tried as it was thought that BER disruption via PARP inhibition would synergize with chemotherapy [58, 60]. However, when PARPi are combined with chemotherapy, full doses of both regimens are rarely achieved as they both have overlapping myelosuppressive toxicities [61].

Hence PARPi combinations with biologics like antiangiogenics or PI3 kinase pathway inhibitors or immune checkpoint inhibitors and other biologic agents are under way, especially for HSGOC, in the hope of inducing greater DNA damage and HRD with lesser toxicities than chemotherapy combinations [11]. Phase I studies of olaparib in combination with the PI3K inhibitor BKM120 (NCT01623349) and the AKT inhibitor AZD5363 (NCT02208375) have demonstrated evidence of activity in OC [62, 63].

Olaparib alone or in combination with cediranib was tested in a phase 2 study in platinum-sensitive recurrent HGSOC (both germline and sporadic BRCA positive) (NCT01116648). Median PFS was 17.7 months for cediranib and olaparib group (\( n = 44 \)) versus 9.0 months for olaparib group (\( n = 46; \) HR = 0.42; \( p = 0.005 \)). Though OS data were not mature at the time of reporting, the combination group demonstrated a trend toward longer OS [7, 11, 64].

Based on these positive results, two phase III trials are underway in both platinum sensitive and platinum resistant OC. Olaparib or cediranib alone or in combination compared with standard chemotherapy is being tested in platinum-resistant EOC in a randomized phase II/III trial, NRG-GY005 (NCT02502266). Olaparib versus olaparib/cediranib versus platinum doublet in BRCA stratified platinum sensitive recurrent HGSOC is being tested in NRG-GY004 (NCT02446600) trial. The phase III PAOLA – 1 trial (see Table 4) (NCT02477644) is evaluating a combination of Olaparib and Bevacizumab maintenance post platinum-based chemotherapy in 1st line Ovarian cancer irrespective of BRCA status [11, 66].
| Trial name | PARPi (approval status) | Mono/Combo; Phase; PARP enzyme targeted | Patient population and key eligibility | N | Treatment arms | Primary endpoint | Results/Trial status |
|------------|-------------------------|----------------------------------------|----------------------------------------|----|----------------|-----------------|---------------------|
| Study 42 (NCT01078662) [56] | Olaparib (approved) | Mono; PARP 1 > PARP2 > PARP3 | Confirmed genetic BRCA1 and/or BRCA2 mutation | 298 | Olaparib 400 mg (8 × 50 mg capsules), oral BID until progression of the disease | Tumor response rate | ORR was 34% (46/137; 95% CI: 26–42) and median DoR was 7.9 (95% CI 5.6–9.6) months |
| LIGHT study (NCT02983799) [57] | Olaparib (approved) | PARP 1 > PARP2 > PARP3 | gBRCAm and wt PSROC HGS | 260 | Olaparib 300 mg after ≥1 L PBC | ORR | Ongoing; study completion 2020 |
| SOLO3/ NCT02282020 [11] | Olaparib (approved) | Mono; Phase III; PARP 1 > PARP2 > PARP3 | gBRCAm PSROC | 411 | Olaparib vs. physician’s choice of single agent standard of care non-platinum based chemotherapy (TPC) after ≥2 L PBC | ORR | ORR 72% olaparib vs 51% TPC OR 2.33 (1.40, 4.58) p = 0.002 PFS 13.4 vs 9.2 mo HR 0.62 (0.43, 0.91); P = 0.013 |
| NCT01081951 | Olaparib (approved) | Combo; Phase II; PARP 1 > PARP2 > PARP3 | PSROC (both germline BRCA and sporadic) | 162 | 200 or 400 mg BID olaparib + C + Pac vs C + Pac as first line | PFS | Prelim results: Median PFS 12.2 (olaparib arm) versus 9.6 mos (no olaparib) p = 0.0012; study completion Dec 2018 |
| NRG-GY005 (NCT0250226) | Olaparib (approved) | Combo; Phase III; PARP 1 > PARP2 > PARP3 | Platinum resistant recurrent high-grade OC | 680 | Olaparib/cediranib versus single agent chemotherapy | PFS (phase II) OS (phase III) | Ongoing; study completion 2023 |
| NCI-OVM1403/NRG-GY004 (NCT0244660) | Olaparib (approved) | Combo; Phase III; PARP 1 > PARP2 > PARP3 | PSROC HGS; BRCA stratified | 549 | Olaparib versus olaparib/cediranib versus platinum doublet | PFS | Ongoing; study completion Dec 2019 |
| ENGOTOV24/AVANOVA (NCT02354131) | Niraparib (investigational; approved only for maintenance) | Combo; Phase III; PARP1 and PARP2 | PSROC | 108 | Niraparib versus niraparib-bevacizumab | PFS | Ongoing; study completion 2020 |
| ARIEL 2 (Part 1: results available; Part 2 ongoing) (NCT01891344) [53] | Rucaparib (approved) | PARP 1 >>>> > PARP2 | PSROC HGS | 493 | 600 mg BID rucaparib | PFS | Prelim results: PFS in the BRCAm (HR 0.27, 95% CI 0.16–0.44, p < 0.0001) LOH high (0.62, 0.42–0.90, p = 0.011) |
| ARIE4/NCT02855944 | Rucaparib (approved) | Mono; Phase III; PARP 1 >>>> > PARP2 | BRCAm HGSOc (platinum sensitive and resistant) | 345 | Rucaparib vs PBC | PFS | Ongoing; study completion 2024 |
| NCT01113957 | Veliparib (investigational) | Combo; PARP 1 and PARP2 | Recurrent HGSOc (both germline BRCA and sporadic allowed) | 168 | [1] Veliparib and temozolomide vs. [2] PLD | ORR | Results not available |
| NCT01306032 [58] | Veliparib (investigational) | Combo; PARP 1 and PARP2 | Recurrent HGSOc (both germline BRCA and sporadic allowed) | 75 | Oral cyclophos 50 mg + veliparib 60 mg daily vs. Oral cyclophos 50 mg daily | ORR | Well tolerated with some clinical activity; addition of veliparib at 60 mg daily did not improve either the response rate or the median PFS |

PARPi: Poly ADP-ribose polymerase inhibitor; PLD: pegylated liposomal doxorubicin; Cyclophos: cyclophosphamide; CI: confidence interval; DoR: duration of response; N: patient accrual; wt: wild-type BRCA; gBRCAm: BRCA germline mutation carrier; BRCAm: BRCA mutant; PFS: progression free survival; ORR: overall response rate; HGSOc: high-grade serous ovarian cancer; PSROC: platinum sensitive recurrent ovarian cancer; HR: hazard ratio.
| Trial name [ClinicalTrials.gov identifier] | Drug (approval status) | Mono/Combo; Phase; PARP enzymes targeted | Patient population; newly diagnosed/recurrent and key eligibility | N | Treatment arms | Primary endpoint | Results/Trial status |
|------------------------------------------|------------------------|------------------------------------------|-----------------------------------------------------------------|----|----------------|-------------------|---------------------|
| SOLO-2 (NCT01874353) [51]               | Olaparib (approved)    | Mono; Phase III; PARP 1 > PARP2 > PARP3 | PSROC, HSG, ≥2 PBC BRCAm only, gBRCAmut BRCA1: Ola:132 (67%)  PBO: 61 (62%)  BRCA2: Ola: 58 (30%)  PBO: 35 (35%) | 295 | Olaparib 300 mg bid vs placebo maintenance after ≥2 PBC | PFS | Ola vs PBO: 19.3 months (95% CI 16.5–27.3) vs 5.5 months (5.0–5.8); HR (in favor of ola) 0.33; 95% CI 0.24–0.44; p < 0.0001; study completion 2021 |
| SOLO1 (NCT01844986) [11, 65]           | Olaparib (approved)    | Mono; Phase III; PARP 1 > PARP2 > PARP3 | Germline BRCA mutant only, newly diagnosed HGSOc or endometrioid stage III and IV Of 391 patients at interim analysis, centrally confirmed gBRCA1/2 m: 388 somatic gBRCA1/2 m: 2 | 451 | Olaparib 300 mg bid vs placebo maintenance after 1 L PBC | PFS | Primary analysis: 60% vs. 27% in ola vs PBO (HR for disease progression or death, 0.30; 95% CI, 0.23 to 0.41; p < 0.001); Ongoing; study completion 2023 |
| PAOLA1/ENGOT/GCIG (NCT02477644) [66]   | Olaparib (approved)    | Combo; Phase III; PARP 1 > PARP2 > PARP3 | Newly diagnosed HGSOc | 612 | Bev or bev/olaparib maintenance after 1 L platinum/taxane/bev | PFS | Ongoing; study completion 2022 |
| ICON 9 trial (NCT03278717)              | Olaparib (approved)    | Combo; Phase III; PARP 1 > PARP2 > PARP3 | PSROC | 618 | Olaparib or olaparib/cediranib maintenance after 1 L PBC | PFS and OS | Ongoing; study completion 2023 |
| ENGOT-OV26/PRIMA (NCT02655016) [67]    | Niraparib (approved)   | Mono; Phase III; PARP1 and PARP2 | HRD positive, stage III and IV | 305 | Niraparib vs placebo maintenance after 1 L PBC with PR or CR | PFS | Ongoing; study completion Aug 2019 |
| GOG-3005 (NCT02470585) [11]            | Veliparib (investigational) | Combo; Phase III; PARP1 and PARP2 | Advanced HGSOc, both BRCA germline mutation carriers and BRCA wild types | 1140 | Veliparib vs placebo maintenance after 1 L (C + Pac) or (C + Pac + veliparib) | PFS | Ongoing; study completion 2020 |

**PARPi** Poly ADP-ribose polymerase inhibitor, C carboplatin, bev Bevacizumab, Psc paclitaxel, PLD pegylated liposomal doxorubicin, PBC platinum-based chemotherapy, 1 L first-line, N patient accrual, wt wild-type BRCA, gBRCAm BRCA germline mutation carrier, BRCAm BRCA mutant, PFS progression free survival, ORR overall response rate, OS overall survival, HGSOc high-grade serous ovarian cancer, PSROC platinum sensitive recurrent ovarian cancer, HRD homologous recombination deficiency, HR hazard ratio, CI confidence interval, bid twice daily, od once daily, nira niraparib, ruca rucaparib, PBO placebo, PR partial response, CR complete response
### Third-line and beyond in EOC – the unmet need
Patients with EOC having 3 or more recurrences have few effective treatment choices. Thus, several clinical trials are investigating treatment options in EOC for these patients. Various single and combination agents are being tried in late stage trials namely PARPi (ricaparib, niraparib, and olaparib), NUC-103 (gemcitabine prodrug), mirvetuximab soravtansine (an antibody-drug conjugate targeting the folate-alpha receptor), trabectedin (novel alkylating chemotherapy agent), birinapant (SMAC mimetic and IAP inhibitor), and volasertib (PI3K inhibitor) [25].

Ovarian cancer with BRCA1/2 mutations can also recur after ≥3 lines of therapy, BRCA1/2 mutant EOC has shown susceptibility to PARP inhibitors due to synthetic lethality (Table 5). In a phase 2 study (Study 42, NCT01078662), olaparib has shown positive results in germline BRCA1/2 mutant positive OC patients with ≥3 recurrences and stratified by platinum sensitivity [56].

### Table 5 PARPi Maintenance by HRD Status

| Study          | Phase  | Patient population                                      | Treatment arms | HR classification | PFS/OS/ORR                                                                 |
|----------------|--------|--------------------------------------------------------|----------------|-------------------|---------------------------------------------------------------------------|
| Study [12, 68] | II     | Platinum-sensitive recurrent serous ovarian cancer; ≥2 PBC with PR or CR to most recent PBC | olaparib 400 mg bid vs PBO | Germline or tumor BRCA Ola: 74 (56%) vs PBO 62 (50%) | PFS: ola; 11.2 months (BRCAm)/7.4 months (wt) p < 0.00001, For PBO: 4.3 months (BRCAm)/5.5 months (wt); p = 0.007 |
|                |        |                                                        |                |                   | OS: BRCAm ola vs PBO 34.9 months (95% CI 29.2–54.6) vs 30.2 months (23.1–40.7); HR 0.62 (95% CI 0.41–0.94) nominal p = 0.025BRCAwt in11 (15%) of 74 patients with BRCAm who received ola maintenance for ≥5 years: ola vs PBO: 24.5 months (19.8–35.0) vs 26.6 months (23.1–32.5); HR 0.83 (95% CI 0.53–1.24); nominal p = 0.37                                                                                                                                                               |
| SOLO1 (NCT01844986) | III    | Newly diagnosed HGSOC or endometrioid stage III and IV | olaparib 300 mg bid vs PBO | OF 391 patients at interim analysis, centrally confirmed gBRCA1/2 m: 388 somatic BRCA1/2 m: 2 | PFS: Primary analysis: 60% vs. 27% in ola vs PBO (HR for disease progression or death, 0.30; 95% CI, 0.23 to 0.41; p < 0.001) |
|                |        |                                                        |                |                   | In 286 patients with BRCA1/2 (Ola: 190; PBO: 96), median PFS Ola vs PBO (19.3 months [95% CI 16.5–27.3] vs 5.5 months [5.0–5.8]; HR [in favor of ola] 0.33, 95% CI 0.24–0.44; p < 0.0001)                                                                                                                                                               |
| SOLO-2 [51]   | III    | PSROC: HSG; ≥2 PBC                                       | olaparib 300 mg bid vs PBO | gBRCAmut BRCA1: Ola:132 (67%); PBO: 61 (62%) BRCA2: Ola: 58 (30%); PBO: 35 (35%) | Median PFS gBRCAm 21 mo (nira) vs 5.5 months (PBO) (HR, 0.27; 95% confidence interval [CI], 0.17 to 0.41), p < 0.00001; Non-gBRCAm HRD+ 12.9 months (nira) versus 3.8 months (PBO) (HR 0.38 95% CI, 0.24 to 0.59), p < 0.00001; All Non-gBRCAm 9.3 months (nira) versus 3.9 months (PBO) (HR 0.45; 95% CI, 0.34 to 0.61), median PFS 8.4 months (nira) vs 4.2 months (PBO) (HR 0.34; 95% CI, 0.24 to 0.44; p < 0.0001). |
| ENGOT-OV16/NOVA [52] | III    | PSROC                                                  | Niraparib 300 mg vs PBO o.d | BRCA1/2 positive & BRCA1/2 negative gBRCA cohort: 203 (niraparib: 138;PBO: 65) non-gBRCA cohort: 350 (niraparib: 234, PBO: 116) | Median PFS in gBRCA-mut niraparib vs PBO 16.6 mo (95% CI 13.4–22.9) vs. 5.4 mo (95% CI 3.4–6.7) (HR 0.23 [95% CI 0.16–0.34]; p < 0.0001) HRD carcinoma ruca vs PBO: 13.6 mo (10.9–16.2) vs. 5.4 mo (5.1–5.6) (HR 0.32 [0.24–0.42]; p < 0.0001). |
| ARIEL3 (NCT01968213) | III    | PSROC: HSGOC, ≥2 prior PBC with PR or CR to most recent PBC | Rucaparib maintenance therapy 600 mg p.o. b.i.d. vs PBO | HRD stratification at the time of enrollment (BRCAmut: Rucaparib/ LOH high; BRCAwt/ LOH low) Rucaparib ruca: 130 [35%] vs PBO: 66 [35%] HRD carcinoma ruca: 236 [63%] vs PBO: 118 [62%] | Median PFS in BRCA-mut rucaparib vs PBO 16.6 mo (95% CI 13.4–22.9) vs. 5.4 mo (95% CI 3.4–6.7) (HR 0.23 [95% CI 0.16–0.34]; p < 0.0001) HRD carcinoma ruca vs PBO: 13.6 mo (10.9–16.2) vs. 5.4 mo (5.1–5.6) (HR 0.32 [0.24–0.42]; p < 0.0001). |

**Abbreviations:** AE adverse event, bid. twice daily, od once daily, p.o. orally or per mouth, chemo chemotherapy, HRD homologous recombination deficiency, HR hazard ratio, IV intravenous, LOH loss of heterozygosity, mut mutated, N/A not available, mo months, ORR overall response rate, PARP Poly (ADP-ribose) polymerase, PFS progression-free survival, po. by mouth, wt wild type, gBRCA germline BRCA mutation, non-gBRCA non-germline BRCA mutation, PSROC platinum sensitive recurrent ovarian cancer, HR hazard ratio, PBC platinum based chemotherapy, Ola olaparib; nira: niraparib; ruca: rucaparib, PBO placebo, PR partial response, CR complete response
Olaparib demonstrated ORR of 46, 30 and 14% in patients considered platinum sensitive (but not considered suitable to receive further PBC), platinum resistant, and platinum refractory, respectively. ORRs with olaparib were in the range of 50–57% and 31–39% for platinum-sensitive and platinum-resistant patients, respectively. Patients who received ≥6 prior lines of therapy had much lower ORR of 20 and 13% for platinum-sensitive and platinum-resistant patients, respectively. Median PFS was 9.4 months (95% CI 6.7–11.4) and 5.5 months (95% CI 4.2–6.7) in platinum-sensitive and platinum-resistant patients, respectively [56].

The results of these trials may open new treatment opportunities for EOC with unmet needs. Also, the concept of maintenance therapy is likely to prolong time to recurrence by treating with therapies approved in this setting during the window when the response to previous line chemotherapy is still lingering.

To provide benefit in this setting, US FDA has accepted the concept of maintenance therapy and has been granting accelerated approvals to drugs for both recurrent EOC and for maintenance therapy setting [25].

Role of PARP inhibitors in maintenance therapy

Approved therapies (Table 5)

All 3 PARP inhibitors – olaparib, niraparib and rucaparib have been approved as maintenance monotherapies in patients with PSROC [13, 15, 51].

Olaparib

Of all the PARPi, olaparib has been the most extensively tested molecule in the clinical setting with favorable results [51]. Olaparib is a potent PARPi that is selectively cytotoxic to cells, blocks PARP from repairing damaged single-strand DNA breaks and preserves repair of efficient cells expressing deleterious BRCA1/2 [70].

The accelerated olaparib approvals came based on positive results from phase 3 SOLO2 and phase 2 Study 19 [12, 51]. SOLO2 investigated olaparib maintenance after ≥2 lines of chemotherapy for OC patients with germline BRCA mutations. The study demonstrated that olaparib significantly improved PFS (Investigator assessed) compared to placebo (19.1 months vs. 5.5 months; HR = 0.30 [95% CI 0.22–0.41], p < 0.0001) with marked improvement in quality of life. The most common AEs of grade 3 or worse severity were anemia (19% in olaparib group vs 2% in the placebo group), neutropenia (5% vs 4%) and fatigue or asthenia (4% vs 2%). Serious adverse events were experienced by 18 and 8% of patients in the olaparib and placebo group, respectively [51]. OS results have not yet been reported [51, 71]. In the phase 2 Study 19 (AZ19/ NCT00753545), in patients with OC irrespective of BRCA status, olaparib increased PFS compared with placebo (median PFS 8.4 months versus 4.8 months; HR = 0.35; 95% CI 0.25–0.49; p < 0.0001) [12].

The phase III SOLO-1 trial evaluated the efficacy of olaparib as maintenance therapy in patients with newly diagnosed advanced HGSOC with BRCA1, BRCA2, or both (BRCA1/2) mutations who had a complete or partial clinical response after PBC. The recently published results of SOLO-1 demonstrated that the olaparib group had 70% lower risk of disease progression or death than with placebo group after a median follow-up of 41 months. The Kaplan–Meier estimate of the rate of freedom from disease progression and from death at 3 years was 60% in olaparib and 27% in the placebo group (PFS NR vs 13.8 months in placebo arm; HR for disease progression or death, 0.30; 95% CI, 0.23 to 0.41; p < 0.001) [65]. The olaparib arm had an unprecedented estimated 36 month benefit over placebo arm in PFS. The median time to the first subsequent therapy or death was 51.8 months vs 15.1 months in the olaparib vs placebo group, respectively (HR, 0.30; 95% CI, 0.22 to 0.40) and this benefit seemed to be maintained in the PFS2 as well, in spite of the fact that 35% of the patients in the placebo arm received a post progression PARP inhibitor (31% maturity, HR, 0.50; 95% CI, 0.35 to 0.72; p < 0.001) [65].

Since 2016, the NCCN [3] has included olaparib in its guidelines as a fourth-line treatment for women with EOC who carry a deleterious BRCA1/2 gene (both germ-line and somatic). In February 2018, the approval for use as maintenance treatment came regardless of patients’ BRCA mutation status thus increasing its reach to a wider set of population [6, 72].

In 344 patients with newly diagnosed germline BRCA mutant HGSOC or endometrioid stage III and IV, olaparib versus placebo maintenance is being tested early post PBC in SOLO1 (NCT01844986) trial [11].

Niraparib

The accelerated niraparib approvals came based on positive results from the phase 3 NOVA study which compared response in germline BRCA (gBRCA) mutation positive and negative patients. While patients on both groups showed significant benefit, those in the gBRCA cohort, showed significantly longer PFS than placebo [52]. OS results have not yet been reported [50]. Approximately two thirds of patients did not have germline BRCA mutations. PFS (by BICR) in the germline BRCA mutations versus placebo was 21.0 months vs 5.5 months (p < 0.0001). In the group with non-mutated BRCA but with HRD positive score versus placebo, PFS was 12.9 months vs 3.8 months (p < 0.0001). PFS was longer in niraparib-treated patients (6.0 versus 3.9 months, p = 0.02) even in the group without mutations and HRD negative. In patients with germline BRCA mutations versus those without mutations, niraparib reduced the risk
of progression or death by 74% (HR = 0.26) vs 55% (HR = 0.45). Majority of AEs were hematological and could be successfully managed by dose modification. Thus, niraparib use is independent of BRCA status and HRD score [50, 52]. Additionally, early use of niraparib versus placebo as maintenance post-response to first-line PBC is being tested in 305 patients with HRD positive, stage III and IV newly diagnosed OC in the ENGOT-OV26/PRIMA (NCT02655016) trial [67].

Rucaparib On April 6, 2018 FDA approved rucaparib as maintenance therapy for recurrent EOC [14]. Approval was based on the ARIEL3 study with similar enrollment criteria as olaparib and niraparib maintenance therapy studies. However, the enrollment was not dependent on BRCA status. In the phase III ARIEL3 [NCT01968213] trial, the median PFS of maintenance rucaparib versus placebo group was 10.8 months vs 5.4 months. The median PFS was higher in patients with germline or somatic BRCA mutations: 16.6 months (95% CI 13.4–22.9) vs 5.4 months (95% CI 3.4–6.7) in maintenance rucaparib versus placebo group, respectively. The PFS was 13.6 months (HR = 0.32, p < 0.0001) in the HRD-group (including BRCA mutant or BRCA wild type/LOH-high) and 10.8 months (HR = 0.37, p < 0.0001) in the “intent to treat” group (including BRCA mutant, BRCA-wild type and LOH-low, indeterminate or high) [73]. These patients also experienced a 77% reduction in the risk of progression or death with rucaparib versus placebo (HR, 0.23; 95% CI 0.16–0.34; p < .0001). To determine the HRD status, the FDA concurrently approved the complementary diagnostic test, FoundationFocus™ CDx BRCA LOH [54, 59].

Foote et al. (2018) assessed the relative value of maintenance therapies and biomarkers in PSROC and presented the results at the 49th Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancers in March 2018. The value of each drug and biomarker in maintenance setting of EOC was validated using the American Society of Clinical Oncology (ASCO)’s Net Health Benefit (NHB) and the European Society of Medical Oncology (ESMO)’s Magnitude of Clinical Benefit Scale (MCBS). The following drugs and trials were examined: Study 19, NOVA, SOLO2, and ARIEL3 trials for PARPi, OCEANS, and GOG 213 trials for bevacizumab treatments, ICON6 for cediranib [74].

In germline/somatic-BRCA mutation cohorts being treated with maintenance PARPi had the highest ASCO scores: olaparib (SOLO2) = 47, (Study 19) = 62; niraparib (NOVA) = 50; rucaparib (ARIEL3) = 54. ESMO scores were also high for maintenance PARPi in germline/somatic-BRCA mutation cohorts. Low value scores were seen for bevacizumab, cediranib, and wild-type BRCA [74].

Based on their efficacy and safety profile and ease of oral administration PARPi are emerging as a potential maintenance therapy in recurrent EOC with response to ≤2 prior lines of PBC [11]. However, despite their advantage as a safe and efficacious maintenance treatment in EOC, PARPi are costlier than the other available therapies. PARPi are 18.8, 6.9, and 2.2–2.7 times costlier than paclitaxel, pembrolizumab, and bevacizumab, respectively. Hence, it is important to carefully select the patients and optimize the timing of PARPi maintenance in order to give the most adequate response [75].

PARP inhibitor therapies in clinical development (Table 3) Veliparib, an oral PARP1 and PARP2 inhibitor has demonstrated a response rate of 26%, with a median PFS of 18.8 months in phase 2 study as monotherapy in relapsed germline BRCA mutant OC, but results need to be validated in larger phase 3 trials [55].

Talazoparib, another oral PARP1 and PARP2 inhibitor was studied in phase 1 trials and showed some clinical activity in relapsed gBRCA mutant OC. However, currently it is not being actively pursued [11].

PARP inhibitors for maintenance therapies in clinical development (Table 4) In women with PSROC, maintenance olaparib in combination with cediranib is currently being tested in ICON 9 trial (NCT03278717). Various combination trials testing early use of maintenance therapy in newly diagnosed OC in response to first-line therapy are underway. The GOG-3005 (NCT02470585) trial is testing veliparib versus placebo maintenance therapy following carboplatin and paclitaxel or carboplatin, paclitaxel, and veliparib in 1100 patients with advanced HGSOC, both BRCA germline mutation carriers and BRCA wild types.

Summary There is adequate data to support maintenance treatment in recurrent EOC, and the use of PARPi in the treatment (olaparib and rucaparib) and maintenance (olaparib, rucaparib, and niraparib) setting for platinum-sensitive HGSOC regardless of BRCA status or HR deficiency in relapsed platinum sensitive ovarian cancer. The recently reported results of SOLO − 1 marks the foray of olaparib as an effective maintenance therapy in newly diagnosed gBRCA positive ovarian cancer patients who are in CR or PR to 1st line surgery and platinum-based chemotherapy. The AEs with all the PARPi can be majorly managed with dose interruptions or modifications. Olaparib is the most studied safe and efficacious treatment and maintenance therapy in the platinum sensitive setting. Though many combination therapies with PARPi are under trial, there is no trial-based comparison
among these three approved PARPi. Hence the relative efficacy or toxicity of the individual drugs is not known. Several trials testing PARPi early in maintenance therapy are in progress and their results will shed light on the optimal timing of maintenance therapy that gives the most benefit with least toxicity. Right patient selection for maintenance treatment is also a challenge. Hence, though PARPi are emerging as a promising maintenance treatment in recurrent EOC with prolongation of PFS, results from further trials are awaited to fulfill the gaps in understanding the role of this pathway in treatment of EOC.

Acknowledgements
The authors thank AstraZeneca Pharma India Ltd, Bangalore for providing medical writing assistance in the development of this manuscript, in collaboration with Turacoz Healthcare Solutions, Gurugram, India.

Authors’ contributions
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Funding
The preparation of this article and funding of the journal’s article processing charges was supported by AstraZeneca Pharma India Limited.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
Sudeep Gupta declares institutional financial interests for conducted research from: Roche, Sanofi, Johnson & Johnson, Amgen, Celltrion, Oncostent, Novartis, Intas, Eisai, Bioccon, AstraZeneca and non-remunerated activities (Advisory Board) from: Roche, Sanofi, Dr. Reddy’s, Novartis, Intas, Lisovska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):117–38.

Krygiou M, Salanti G, Pavlidis N, Parakevaidis E, Ioannidis JP. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 2006;98(22):1635–63.

Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17(12):1147–58.

Tayama S, Motohara T, Narantuya D, et al. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. Oncotarget. 2017;8(27):44312–25.

Evans T, Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol. 2017;9(4):533–67.

Ledermann J, Harter P, Gouley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61.

Olaparib Prescribing Information by FDA. LYNPARZA® (olaparib) tablets, for oral use. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/20658s001lbl.pdf.

Rucaparib Prescribing Information F. RUBRACA™ (rucaparib) tablets, for oral use 2016. Niraparib Prescribing Information F. ZEJULATM (niraparib) capsules, for oral use. 2017.

Bider BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: clinical utility and possibilities of overcoming resistance. Gynecol Oncol. 2017;147(3):695–704.

Lokadassum R, James FY, Narayan G, Prabhakaran PK. Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments. Ecmancermedicalscience. 2016;106:266.

Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31:14.

Abu Hassan SO, Nielsen DL, Tuxen MK, Petersen PH, Soletormos G. Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period. Future Sci OA. 2017;3(3):FSO216.

Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OVIS/EOCIT 5995S): a randomised trial. Lancet. 2010;376(9747):1155–63.

Neff RT, Senter L, Salari R. BRCA mutation in ovarian cancer testing, implications and treatment considerations. Ther Adv Med Oncol. 2017;8(5):519–31.

Singh G, Thota N, Singh S, et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations. Breast Cancer Res Treat. 2018;170(1):189–96.

Chuang YT, Chang CL. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance. Taiwan J Obstet Gynecol. 2012;51(3):336–41.

Tomao F, D’Incalci M, Biagioli E, Peccatori FA, Colombo N. Restoring platinum sensitivity in recurrent ovarian cancer: by extending the platinum-free interval: myth or reality? Cancer. 2017;123(18):3450–9.

Herzog TJ, Monk BJ. Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need? Gynecol Oncol Res Pract. 2017;4:13.

Bruchim I, Jarchowhsky-Dolfberg O, Fishman A. Advanced (2nd-line) chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2013;166(1):94–9.

Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8.

Hankor LC, Loibl S, Burchardt N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–12.

Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21(4):771–5.

Pignata S, Lorusso D, Scambia G, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory
advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16(10):561–8.

31. Pignata S, Scambia G, Bologna A, et al. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNoG, BDG0-Ov1, AGO-Ovar2:16, ENGOT-Ov1, GCIG study. J Clin Oncol. 2017;35(29):3347–53.

32. Monk BJ, Herzog TJ, Kaye SB, et al. Trebedinplus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012;48(15):2361–8.

33. Teplinsky E, Herzog TJ. The efficacy of trebeinidin in treating ovarian cancer. Expert Opin Pharmacother. 2017;18(3):313–23.

34. AVASTIN® (bevacizumab). Prescribing Label F. AVASTIN® (bevacizumab). Prescribing Label. 2004. https://www.accessdata.fda.gov/druginfo_data_docs/label/2009/125056s0169lbl.pdf.

35. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(7):2039–45.

36. Aghajanian C, Goff B, Nyrcum LR, Wang YC, Hussein A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139(1):10–6.

37. Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology/gynecologic oncology group study: COG-OVAR13): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–91.

38. Wu YS, Shi L, Shen D, Chen X. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2018;9(6):10703–13.

39. Qian X, Qin J, Pan S, Li X, Pan Y, Ma S. Maintenance therapy in ovarian cancer with targeted agents improves PFS and OS: a systematic review and meta-analysis. PLoS One. 2015;10(9):e0139026.

40. Chan SL, Mok T. PARP inhibition in BRCA-mutated breast and ovarian cancer. Lancet Oncol. 2016;17(2):e57–74.

41. Wu YS, Shui L, Shen D, Chen X. Bevacizumab combined with chemotherapy for ovarian cancer. Int J Women's Health. 2016;8:305.

42. Hope JM, Blank SV. Current status of maintenance therapy for advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199–203.

43. Karen Anne Cadoo CA, Fraser C, Milner A, Kolvenbag B. A phase 2 study to assess olaparib by homologous recombination deficiency status in patients with platinum-sensitive, relapsed, ovarian, fallopian tube, or primary peritoneal cancer. Journal of Clinical Oncology. 2017;35:15.

44. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without nintedanib for advanced ovarian cancer. J Clin Oncol. 2014;32(30):3374–85.

45. Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus placebo in patients with platinum-sensitive recurrent ovarian cancer. Lancet. 2014;383(9930):916–22.

46. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in patients with platinum-sensitive recurrent ovarian cancer and three or more lines of prior therapy. Oncotarget. 2017;8(34):57483–505.

47. Karen Anne Cadoo CA, Fraser C, Milner A, Kolvenbag B. A phase 2 study to assess olaparib by homologous recombination deficiency status in patients with platinum-sensitive, relapsed, ovarian, fallopian tube, or primary peritoneal cancer. Journal of Clinical Oncology. 2017;35:15.

48. Swan EM, McNeilh IA, Coleman RL, et al. A randomized clinical trial to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response. 2014;32(15_suppl):TPS5619-TPS5619.
70. Fong PC, Yap TA, Boss DS, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512–9.

71. Michael Friedlander VG, Gibbs E, Bloomfield R, Hilpert F, Wenzel LB. Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC; SOLO2 phase III trial. J Clin Oncol. 2017;35(15):5503–7.

72. LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer. AstraZeneca and Merck’s New LYNPARZA Tablet Formulation Recommended for Maintenance Therapy Regardless of BRCA Status [press release]. 2018.

73. Rucaparib Boosts Progression-free Survival in BRCA Mutant Recurrent Ovarian Cancer. https://www.esmo.org/Conferences/Past-Conferences/ESMO-2017-Congress/Press-Media/Press-Releases/Rucaparib-Boosts-Progression-Free-Survival-BRCA-Mutant-Recurrent-Ovarian-Cancer [press release]. 2017.

74. AA-S JRF, Liang ML, Ehrtman JA, Cohn DE, Jewell E, Havrilesky LJ. Bevacizumab, TKI, or PARPi? A targeted approach using composite value-based endpoints and biomarkers to individualize care for platinum-sensitive recurrent ovarian cancer (PSROC). Gynecol Oncol. 2018;149(1):10–1.

75. Juliet Elizabeth Wolford JB, Lindsey E. Minion, Robin Keller, Ramez Nassef Eskander, John K. Chan, Bradley J. Monk, Krishnansu Sujata Tewari. Abstract No: 5508, Cost-effectiveness of maintenance therapy in advanced ovarian cancer. Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab. 2018 ASCO Annual Meeting 2018; http://abstracts.asco.org/214/AbstView_214_220873.html.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.